Clinical trials
Phase 1/2 Kidney Neoplasms trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
52 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 3 |
| 2001 | 1 |
| 2002 | 1 |
| 2003 | 1 |
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 3 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 3 |
| 2011 | 1 |
| 2014 | 4 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 3 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 5 |
| 2024 | 4 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 26 |
| Terminated | 13 |
| Recruiting | 7 |
| Active, not recruiting | 5 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 6 |
| Memorial Sloan Kettering Cancer Center | 4 |
| Argos Therapeutics | 2 |
| Fred Hutchinson Cancer Center | 2 |
| Ludwig Institute for Cancer Research | 2 |
| 7 Hills Pharma, LLC | 1 |
| A2 Biotherapeutics Inc. | 1 |
| Ajjai Alva, MD | 1 |
| Amgen | 1 |
| Aravive, Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Kidney Neoplasms | 52 |
| Carcinoma, Renal Cell | 31 |
| Breast Neoplasms | 10 |
| Melanoma | 10 |
| Carcinoma, Non-Small-Cell Lung | 9 |
| Neoplasm Metastasis | 9 |
| Ovarian Neoplasms | 9 |
| Prostatic Neoplasms | 7 |
| Sarcoma | 7 |
| Colonic Neoplasms | 6 |
Trials
Showing 1 to 25 of 52. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.